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A 60-year-old Caucasian male with end stage renal disease
resulting from longstanding hypertension underwent his ﬁrst
post-mortal renal allo-transplantation in 2000, which was
complicated by a steroid resistant acute rejection episode and
subsequently resulted in transplantectomy within 3 months
thereafter. In 2003, he underwent his second post-mortal
renal allo-transplantation. From 2006 on he suffered from
recurrent episodes of transplant pyelonephritis. In course of
time his serum creatinine rose slowly and proteinuria
developed. In 2008 a biopsy of the renal allograft showed
chronic interstitial damage and tubulus atrophy compatible
with chronic rejection and pyelonephritis. Between 2011 and
2012 he was admitted eight times for recurrent episodes of
transplant pyelonephritis caused by an Extended Spectrum
beta-Lactamase (ESBL) producing Escherichia coli (E. coli). Each
episode was associated with an acute further decline in renal
function that only partially recovered upon treatment. In
2012 the patient reached end stage renal disease due to graft
failure caused by recurrent transplant pyelonephritis and
chronic allograft nephropathy. He started with peritoneal
dialysis and underwent transplantectomy. Hereafter, he
remained colonised by ESBL producing E. coli in the large
intestine as was shown by at least three rectal cultures
positive for ESBL. As the risk for recurrent pyelonephritis by
ESBL producing E. coli due to persistent colonisation yielded a
relative contraindication for another renal transplant proce-
dure, he was not been placed on the renal transplant waiting
list.
In an attempt to decolonise the patient from the ESBL
producing E. coli, he underwent donor feces infusion in May
2013. Prior to this intervention, the presence of ESBL
producing E. coli in the large intestine was again conﬁrmed
by a positive rectal culture. In addition his throat and perineum
were also screened for the presence of ESBL producing
Enterobacteriaceae, but both were negative. Culture of the
urine was not possible because of the anuric condition of the
patient. The donor feces infusion was performed according to
the protocol as used in the FECAL trial [1]. In summary, donor
feces were obtained from a young healthy Caucasian adult,
who was periodically screened for various infectious and
gastro-intestinal diseases. Feces from the donor were col-
lected and processed within 6 h after production. First, the
feces were diluted with sterile saline, and then poured through
unfolded gauze in a funnel, in order to obtain a solution which
was free of debris and solid particles. This solution was
immediately infused in the patient through a nasoduodenal
tube. Donor feces infusion was preceded by full colon lavage
without prior use of antibiotics.
Within the ﬁrst 2 days after donor feces infusion the patient
experienced mild diarrhoea and abdominal cramps, but no
other adverse events occurred. Follow-up ESBL swab cultures
of the rectum, perineum and throat were taken at week one,
two, four, and twelve after the donor feces infusion. During
these four follow-up time points the ESBL cultures of the
throat and perineum remained negative.
At week one after donor feces infusion, the rectal culture
was still positive for ESBL. However, at week two the rectal
culture became negative for ESBL and the subsequent rectal
cultures remained negative hereafter during twelve weeks of
follow-up. During this same follow-up period, the patient did
not develop any symptoms of urinary tract infection. Thanks to
this successful eradication, the patient is now on the waiting
list for renal transplantation.
Donor feces infusion which is also called fecal microbiota
transplantation and fecal bacteriotherapy, is an intervention
that has been elaborately evaluated against Clostridium difﬁcile
(C. difﬁcile) infection. Most published data about this interven-
tion were case series and case reports of which systematic
reviews were written [2–4]. These systematic reviews
reported that donor feces infusion could be a promising
intervention against C. difﬁcile infection. Additional evidence
was recently provided by the FECAL trial [1] which demon-
strated in an open label randomised controlled trial that donor
feces infusion is indeed very effective against recurrent
C. difﬁcile infection.
Therefore we hypothesised that donor feces infusion is not
only effective against C. difﬁcile, but could also be effective
against ESBL producing Enterobacteriaceae residing in the large
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intestine. To study this hypothesis, a proof of principal study
about the effectiveness of donor feces infusion against the large
intestine colonisation by ESBL producing Enterobacteriaceae is
currently being performed within our hospital.
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